Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
96people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
Imeglimin + other Oral Hypoglycemic Agents (OHAs)
Metformin + other Oral Hypoglycemic Agents (OHAs)
Reported lower long-term blood sugar, no range given−0.50
Reported lower circulating cell-free mitochondrial DNA, no range given−18.5
randomisedthe abstract, start to end
… OHAs, significantly reduced HbA1c (Δ=-0.5%, p=0.001), ccf-mtDNA (Δ=-18.5 copies/μL, p=0.02), and IL-6 …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
HbA1cImeglimin + other Oral Hypoglycemic Agents (OHAs) vs Metformin + other Oral Hypoglycemic Agents (OHAs)
−0.5
Circulating cell-free mitochondrial DNA (ccf-mtDNA)Imeglimin + other Oral Hypoglycemic Agents (OHAs) vs Metformin + other Oral Hypoglycemic Agents (OHAs)
−18.5
Other glucose-loweringGlycemic controlInflammation & biomarkers
1 / 4